Introduction
Hemorrhagic cystitis (HC) is recognized as a significant cause of morbidity and sometimes mortality in patients undergoing hematopoietic SCT (HSCT) [1] [2] [3] shows a clinical manifestation varying from microscopic hematuria to severe hemorrhage with obstructive renal failure. 4, 5 Its reported incidence ranges from less than 10% to more than 70% due to the discrepancies in definition criteria and the types of transplant. 6, 7 Furthermore, severe HC requires prolongation of hospitalization and even finally leads to death.
There exist two forms of HC according to the time of onset and underlying pathogenesis. Early-onset HC occurs within a few days after transplantation and results from urothelial injury induced by chemotherapeutic agents, most commonly CY and ifosfamide, 8 whereas late-onset HC (LOHC) occurs later after transplantation, and is more frequently associated with viral infections. [9] [10] [11] [12] According to the amount of hematuria, HC is graded as mild, moderate or severe. Routine therapy for HC is based on intensive supportive treatment with hyperhydration, constant bladder irrigation, pain management and red cell or platelet transfusions. 2, 13 Encouraging results with antiviral agents have been published; however, there is no evident proof in a large number of patients and mainly improve clinical symptoms. [14] [15] [16] [17] The use of formalin, alum, prostaglandin E1, estrogens, FVIIa, factor XIII, hyperbaric oxygen treatment, intravesicular sodium hyaluronate, recombinant human epidermal growth factor or recombinant human GM-CSF has been described, but their efficacy remains controversial. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Severe HC may also require surgical treatment with cystoscopy and cauterization, and even cystectomy when previous methods have failed, 28 but it is limited by the disadvantage of operation.
Recently, a new technique with selective embolization of the vesical arteries has been successfully performed for the treatment of HSCT patients with severe HC, but only three cases were reported. 29, 30 In the present study, we report our management of selective embolization of the internal iliac arteries in 10 patients with severe HC after HSCT.
Patients and methods

Patients
From February 2004 to July 2007, 10 patients with LOHC receiving HSCT were treated in the study. In addition to the presence of dysuria or (and) lower abdominal pain, HC was graded as previously reported:
23 grade 1, microscopic hematuria on more than two consecutive days; grade 2, macroscopic hematuria; grade 3, macroscopic hematuria with clots; grade 4, macroscopic hematuria with clots and impaired renal function secondary to urinary tract obstruction. LOHC was defined as the occurrence of HC after 10 days of administration of CY. Day 0 was the stem cell infusion day. The criteria for participation in this study included grade 3 or 4 HC, no improvement with forced hyperhydration, platelet and blood cell transfusions, continuous bladder irrigation and pain management. None had a history of urinary tract infection, pelvic irradiation, coagulopathy or evidence of microscopic hematuria before HSCT. Diagnosis of acute GVHD was assessed and graded according to Klingebiel and Schlegel. 31 Type of stem cells and chemotherapy regimens All 10 patients underwent allogeneic transplantation, four from matched related donors, two from matched unrelated donors, four from half identical related donors (mismatched related donors; three from mothers and one from a daughter). The conditioning regimens are shown in Table 1 . All patients were conditioned with CY 1.8 g/m 2 once daily i.v. on days -3 and -4 (total dose 3.6 g/m 2 ), prophylaxis against HC included forced diuresis with vigorous hydration, urine alkalinization and prophylactic mesna. All patients were administered ganciclovir 5 mg/kg twice daily i.v. for 14 consecutive days (total dose 140 mg/ kg) to avoid CMV infection. GVHD prophylaxis consisted of CSA and MTX in four patients who undergoing matched related donors, others received antithymocyte globulin and mycophenolate mofetil together with CSA and MTX.
Transcatheter embolization technique Selective embolization of internal iliac artery was performed by an interventional radiologist under fluoroscopic guidance in an angiography room. Using regional anesthesia, the physician introduces a catheter through the unilateral femoral artery to perform digital angiography of the aortoiliac sector by modified Seldinger's technique. Selective catheterization of the hypogastric arteries with a standard angiographic catheter Cobra 4 F (Cook Incorporated, Bloomington, IN, USA) was then carried out to identify the bilateral vesical arteries and observe their hypervascularization. Subsequently, gelatin sponge microparticles and gelfoam pledgets were carried out to occlude both sets of hypogastric arterial visceral branches, until ceased flow was attained in the local sites. The complete embolization of the vesicular branches but not the entire internal iliac vessel was the goal in the procedure. Then, a further hypogastric angiography was performed to confirm the occlusion of the vesical hypervascularization. Action of the unilateral lower limb was prohibited for over 12 h after the angiography.
Criteria for therapeutic efficacy
Response was judged according to the criteria as follows:
Complete response (CR): hematuria and symptoms ceased after treatment and no recurrence.
Partial response: diminution of hematuria to the point of not requiring transfusion or presence of microscopic hematuria with no symptoms.
No response: no response to treatment or reappearance of hematuria and symptoms immediately after discontinuation of treatment.
Recurrence: start of macroscopic hematuria X1 week after achieving a CR.
Results
Detailed patient characteristics and results are listed in Table 1 . Median age of patients was 32 years (range, . Six patients with CML, one patient with AML and one patient with ALL were pretreated with modified BU/ CY, one patient with ALL and one patient with AML received TBI/CY regimen. In the all 10 patients, five showed a positive reactivation of CMV for over 2 weeks before HC onset, six had acute GVHD at the time of HC onset. Grade 3 HC occurred in seven patients and grade 4 in three patients, respectively. The median time for the onset of HC was 35 days (range, 22-80) after transplantation, median duration of HC before the start of treatment was 20 days (range, 6-51).
In addition to the routine therapy of forced hyperhydration, platelet and blood cell transfusions, continuous bladder irrigation and pain management, all the patients were treated with intravesical instillation of GM-CSF after HC onset. Patients with positive reaction of CMV also received ganciclovir management for over 14 days, and the others received acyclovir for 2 weeks. Patient 2 was treated with hyperbaric oxygenation for 10 days after the first procedure of embolization.
Six patients achieved a CR and two patients achieved a partial response after first treatment of embolization, whereas two patients achieved no response and died of severe pulmonary infection. In patients achieving partial response, a CR was then obtained after a second treatment of embolization. Median time to CR was 26 days (range, 4-180). In all patients who had CR, diminution of hematuria was observed after 15 days of treatment. In case 2, macroscopic hematuria recurred 30 days after the first treatment, a CR was then achieved 22 days after a second treatment. Case 3 was given the second treatment on account of the persistence of microscopic hematuria (Figures 1a and b) . No further therapy was required in all the patients after CR, case 4 died within 2 months after treatment due to grade 4 GVHD, with no presentation of HC at the time of death, seven others remain asymptomatic of HC.
The incidence of all grades of HC was 20.06% in the overall group of 324 patients (65/324); there was no significant difference in the incidence of HC among the various induction regimens. Two patients who died of pulmonary infection had TBI-CY as the induction regimen, and 24 cases had this induction regimen in the entire series of patients, in which 20.83% patients developed grades 1-4 HC (5/24), with no higher incidence of HC existed in the TBI-CY group versus the other induction therapy. Of the two mortalities, case 1 suffered from drug-resistant Acinetobacter baumannii, whereas case 6 died of a mixed infection of Klebsiella pneumoniae and fungus. As our study was limited by the lack of post-mortem examination, there was no evident pathologic proof of the bladder and lung, and there seemed to be no apparent role for the cystitis in the death of these two patients.
There was no incidence of incontinence after the embolization procedure. One patient (case 6) had fever on the second day of treatment, and was soon controlled by the use of antibiotics, and she was later confirmed to have pulmonary infection complication. Two patients complained of mild buttock pain after the procedure, but this resolved immediately within 1 day. No other apparent adverse effects were observed in these patients.
Discussion
HC is a commonly observed complication after HSCT, characterized by the presence of hematuria due to diffuse inflammation of the bladder mucosa, and can be associated with severe morbidity and mortality both in pediatric and in adult population. The incidence of HC in childhood series is lower than that of adult series, because of the lower incidence of latent infection with viruses in younger patients. 3 Viruses are associated with HC. The role of a human polyomavirus is clearly established in adult BMT patients, whereas infection by adenovirus is frequently detected in children. Over the past decades, outcome of early-onset HC is largely improved by the use of 2-mercaptoethane sulfonate sodium (mesna), hyperhydration and forced diuresis. 32, 33 In contrast, LOHC remains a continuing complication for HSCT, which is thought to result mainly from viral infections. The reactivation of polyomavirus such as BK virus has been thought to be the most significant factor in the pathogenesis of LOHC, some other studies provide information of adenovirus, CMV and simian virus 40 as putative agents of HC. [9] [10] [11] [12] Other reported factors include GVHD, unrelated BM or cord blood transplants, radiation and exposure to BU. 1, [34] [35] [36] The Embolization treatment of hemorrhagic cystitis after HSCT Y Han et al immune reactions play an important role in the pathogeneses of LOHC, which may lead to the immune attack of the recipient urothelium, causing more damage than the simple toxic effects of chemotherapy or the cytopathic effects of viral infections. Initially, the toxicity to the uroepithelium and immunosuppression caused by the conditioning regimen provides suitable conditions for viral replication. In contrast, hematopoietic reconstitution leads to immunological reaction against viral antigens expressed on the uroepithelium causing extensive mucosal damage and hemorrhage. 9 All our 10 patients with severe HC enrolled underwent allogeneic transplantation, five had acute GVHD at the time of HC onset, five were detected as positive reactivation of CMV for over 2 weeks before HC onset. Our study suggests probable roles of GVHD, allogeneic HSCT or CMV infection in severe LOHC after HSCT.
Most patients with LOHC resolve finally. However, in some cases, high attention is focused on the fatal outcome of urinary tract obstruction. 4, 37 Despite maximum efforts, effective therapy of LOHC has not been established until now. Base management including hyperhydration, bladder irrigation and transfusional support are often ineffective. Intravesicular formalin appeared effective to treat the patients with severe HC, 18 but it can lead to severe suprapubic pain requiring anesthesia, vesicoureteral reflux, bladder and ureteral fibrosis, bladder rupture with intraperitoneal extravasation of formalin and other side effects. Alum has been used and obtained various successes in some HC patients; 19 however, disadvantages such as allergic reaction, coagulopathy and central nervous system disturbance exist. Prostaglandins E1, E2 and F2 have some success with bladder spasms occurred in 95-100% of the cases. 20, 38, 39 Estrogens application gets improvement of hematuria and CR in Australian patients with severe HC (80 and 60%, respectively), 21 while ineffective result is observed in Chinese patients. 18 Intravesicular sodium hyaluronate or recombinant human epidermal growth factor are other local treatment choices but need to be tested in larger cohorts of patients. 22, 24 Recombinant human GM-CSF in intravesical instillation has been reported to be successful for the treatment of HC, 23 and we treated our patients with intravesical instillation of GM-CSF after HC onset, but no effective result was observed.
Hyperbaric oxygen therapy for HC patients has achieved encouraging success with no adverse effects in recent years, 25 especially for the patients induced from radiation, 40 which allows better tissue diffusion of oxygen, improving neoangiogenesis by increasing the vascular density of irradiated tissues. However, the wide application of this approach is limited by the requirement of a hyperbaric chamber and long procedure (20-30 days). Patient 2 in our group also received hyperbaric oxygenation, but the treatment ceased after 10 days because of his intolerance to the long duration. rFVIIa and FXIII are proposed and have some response in severe HC cases after HSCT, 26, 27 but large randomized studies are needed because of the substantial cost of these products and the lack of adequate monitoring methodology.
Surgical treatment is the final procedure to control life-threatening HC, which includes flexible cystoscopy, evacuation of blood clots, cauterization and cystectomy, 28 but is associated with high morbidity and mortality.
As some viruses are detected in blood and urine samples in LOHC, the administration of antiviral agents has been much tried in recent years, including vidarabine, 14 ribavirin, 15 ganciclovir 16 or cidofovir; 17 however, it is rather difficult for the specific choice of antiviral agents to any HC patient. Ganciclovir prophylaxis is thought to be effective when given to all CMV-positive patients or to patients who were considered at high risk for CMV disease on the basis of a positive surveillance culture. 41 As CMV infection is highly prevalent in Chinese patients, 11 we detected the reaction of CMV in our study, CMV antigen was detected over 2 weeks in five patients before HC onset, and ganciclovir was given for over 14 days, but no evident effect was observed in the related patients, maybe there also exit other pathogens in the onset of HC.
There are other therapies for managing HC, such as silver nitrate 42 and e-aminocaproic acid; 43 however, the risks of ureteral obstruction from silver salts and the accelerated clot formation from e-aminocaproic acid limit their routine usage. Eodymium (Nd) YAG laser was reported to fulgurate bleeding endoscopically for resolving gross hematuria, 44 but it failed to control HC in another study. 45 All of the above therapeutic options have advantages and an appropriate procedure is needed for the treatment of late-onset refractory HC.
Transcatheter arterial embolization is an accepted approach for intractable hemorrhage from pelvic organs, 46 which offers the obvious advantage of a lower rate of morbidity over surgery. Selective, percutaneous embolization of vesical arteries has been successfully performed to control severe hematurias from the urinary bladder secondary to radiation, tumors and trauma. [47] [48] [49] To our knowledge, only three cases with severe HC after HSCT are reported to administrate this technique, two from Spain and one from Italy. All of them resolve from the intractable hematuria by this new treatment and no adverse effects were observed in these procedures. In our study, 10 patients with severe LOHC were performed for selective embolization, where as all the conservative measures for controlling hematuria had failed. Eight of 10 patients (80%) achieved CR, including six from first treatment of embolization, two from second treatment, no further therapy was required in all the patients after CR. In addition, no apparent adverse effect was observed except transient buttock pain in two patients. Fever in one patient was confirmed on account of the complication of pulmonary infection. In our procedure, we used gelatin sponge particles or pledgets but not other methods as the embolic agent for internal iliac artery embolization, which is proved to be safe and can be repeated with maximal maintenance of good renal function. The reasons for our choices are as follows: first, gelatin sponge has been a familiar and cheap embolic agent for Chinese interventional radiologists; second, gelatin sponge can recanalize as quickly as several weeks after administration, occlusion for a shorter period of time may be enough to achieve satisfactory ischemia to prevent further hemorrhage; third, gelatin is an absorbable hemostatic agent, with no toxic or antigenic effects on the body.
Our data indicate an encouraging and safe effect of selective embolization for treating severe HC after HSCT. However, the importance of having an experienced interventional radiologist in attendance should be emphasized to prevent potential complications such as fever, buttock ischemia, hematoma, vascular perforation and infection.
The appearance of recurrence of hematuria (cases 2 and 3) after the first procedure of embolization is probably due to the revascularization and collateral circulation formation in local site. Though the conditioning regimen did not affect the occurrence of HC and there was no higher incidence of HC in the TBI-CY group compared with the other induction therapies. All the four patients underwent HSCT from matched related donors get grade 3 HC and resolved (cases 5, 7, 8 and 9) after first treatment, two patients pretreated with TBI-CY get grade 4 HC and achieved no response, which suggests a significance of pretreatment regiment in the etiopathogenesis and degree of HC, may be the intensive immunosuppression or radiation affects the HC severity and its refractoriness to treatment. The two patients who achieved no response died of pulmonary infection after 2 weeks and 1 month after embolization and lack a second opportunity to receive a second therapy. Therefore, our results suggest that selective embolization of the internal iliac arteries seems to be a suitable method in cases of severe HC refractory to routine therapeutic means, and can be considered as a safe procedure before any surgery is attempted. However, for a better understanding of the therapeutic and adverse effects of selective embolization in LOHC, a larger phase of clinical trial is needed.
